Keine Ergebnisse für „“
Tipp: Versuchen Sie es mit einem gültigen Symbol oder einem bestimmten Firmennamen für relevante Ergebnisse
Deutsche Märkte geschlossen
Euro Stoxx 50
Dow Jones 30
Arrowhead Pharmaceuticals, Inc. (ARWR)
NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
Ab 12:54PM EDT. Markt geöffnet.
1.078 Reaktionen zu Unterhaltung zu $ARWR
Melden Sie sich an, um eine Nachricht zu posten.
from twitter: $arwr $ions discontinuation of ENaC program for more promising pulm targets due to pre-clin LT tox finding. buried in the earnings call, not in the press release, nor in the slide deck. classic.
$ARWR Annual Meeting is tomorrow March 18 at 1 pm PT - looking forward to hearing more good news!
from twitter citi gives us a haircut.. noise imo: Citigroup cuts $ARWR Arrowhead price target to $95 from $110
I’m trying to understand something. Does MRNA technology compete directly with RNAI or do they complement each other at some level? In other words, is there room for both? I keep reading so much about the rapid success and growth of MRNA companies, mostly associated with Covid, but now they’re talking about going after the same indications as $ARWR and other SiRNA technologies. It seems like competition is rapidly building, but RNAI gets much less attention. I wish more people would jump on the RNAI bandwagon. Are they close enough that a company like $ARWR could easily pivot to MRNA depending upon which works better for a particular indication or is the general public just not seeing the light yet?
Wanted to send out some Twitter profiles with a focus on ARWR if some of you are on the platform so you can see some other thoughts/breaking news when it comes. You can always search Twitter with $ARWR and all the post will come up. Some of these are folks on the board here but wanted to send so others could follow. Feel free to add some others I may not know of.
6 weeks ago, $CRSP was at $220. It’s currently trading at $103, down more than 50%. I’ll take $ARWR all day long.
5 Trade Ideas for Monday: Arrowhead Pharma, Boeing, Citgroup, Cree and Grainger
BLUE is teaching you a lesson Goldilocks lesson of therapies
Small molecule -> Too Cold, doesn’t target tissue, systemic toxicity, 5% success rate in clinic
Antisense/RNAi -> Just Right, blocks production at the source and ONLY the source. Off targeting effects are temporary. Probability of trial successes unprecedented
Gene editing -> Too Hot, Off targeting effects permanently damage the genome, bioethics nightmares.
$ARWR is my largest holding with the best upside in the Antisense/RNAi space.
So here’s my question:
Why does $ARWR say that healthy volunteers may give us a better read at this point than only 4 patients, as the HVs don’t present with the mucus build up barriers?
I understand that we will be looking more deeply into lungs with lavage and brushings.
Also from Dough on twitter: @semodough
RBC $ARWR APOC3/ANG3 abstracts from ESC provide incremental data suggesting strong target engagement and triglyceride reductions. Bears like to point out that space is crowded,think ARWR will be best-in-class given superior dosing/safety vs ASO (IONS/PFE/AKCA) and superior
$ARWR Arrowhead price target raised to $90 from $80 at Piper Sandler Piper Sandler analyst Edward Tenthoff raised the firm's price target on Arrowhead Pharmaceuticals to $90 from $80 and keeps an Overweight rating on the shares after the company partnered with Takeda to co-develop and co-commercialize ARO-AAT. The deal is "strong" and has Arrowhead sharing 50/50 profits in the U.S. and receiving 20%-25% royalties on outside the U.S. sales, Tenthoff tells investors in a research note. The analyst estimates Arrowhead now holds pro forma cash of $765M to advance its "rich" RNAi therapeutic pipeline. ·
from dough on twitter: Baird continue to like $ARWR in the RNAi space due to the steady click of clinical events expected over the next 12 months providing multiple potential upside points. After model updates, we reiterate our ARWR Outperform rating and $70 price target.
" Egan tells investors in a research note. Success in either has the potential to validate Arrowhead's lung and/or tumor RNAi delivery technology which would be a "transformational event for the stock and a major source of differentiation from other RNAi companies," says the analyst."
TODAY, FEBRUARY 08, 2021
Arrowhead price target raised to $110 from $90 at Citi
Citi analyst Shawn Egan raised the firm's price target on Arrowhead Pharmaceuticals to $110 from $90 and keeps a Buy rating on the shares following the company's Q1 results. Clinical results in cystic fibrosis and kidney cancer are expected by the end of Q2 and continue to be underappreciated, Egan tells investors in a research note. Success in either has the potential to validate Arrowhead's lung and/or tumor RNAi delivery technology which would be a "transformational event for the stock and a major source of differentiation from other RNAi companies," says the analyst.
Happy New Year from Detroit, Michigan!! Thanks for everybody’s contributions the last year, i am truly blessed to have found $ARWR 2 months ago when I did & i appreciate everyone on this board that has helped me. I believe the sky is the limit here. I have family & friend’s health that depend on this technology & medicine so this investment means a lot more to me then just a few bucks in a few days. Im here for the long haul, meaning, I’ll be here for the next decade! Cannot wait to see all the potential start to unfold! Congrats on your 2019 gains & cheers to a fulfilled & prosperous 2020!
Coldlander 12 days ago
I believe I have found ARO-HSD's first cohort of the single ascending dose schedule. First dose will be March 3rd in New Zealand.
Should find out soon if this is ARO-HSD Trial. Now recruiting @ Auckland
Proton Study Healthy Males and Females
Aged 18 – 55 years
BMI less than 35 kg/m2
Was looking at the name of trial and if there was any association with Proton and fatty liver and found this:
Magnetic Resonance Imaging Proton Density Fat Fraction (PDFF) Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver ...
I'm not sure why people feel that $150 is the tops for this company. If $ARWR can deliver like CA indicates, with 3 drugs per year in and extra tissue types every 18-24 months, along with high success rate like CA says, then this can easily be a $100B company. That's a $1000 stock on a 5 year horizon alone.
$ARWR AAT Article in Monday’s Los Angeles Business Journal - link below - includes quote from Miriam O’Day, chief executive of the Alpha 1 Foundation - the news “brings hope to the Alpha-1 community in the midst of the Covid-19 pandemic.”
Arrowhead’s Liver Drug Shows Early Promise | Los Angeles Business Journal
always some cogent points made on twitter:
from bikerieder: "We ended the FY2020 (232) with 75% more employees than FY2019 (134). And we are more hiring in FY2021. Interested? "
this from Mariano:
"YES! $ARWR harnessing nature’s process of natural gene-silencing (RNAI), utilizing RISC’s catalytic properties. Less drug saturation for intracellular-uptake. Translates to superior drugs with supreme safety. Makes lots of sense (RNAI), maybe more than ANTISENSE."
the sliv puts dirk in the corner: " Dirk is not AGAINST $ARWR. He's just and only FOR himself. He goes long and praises $ARWR at times. Other times, like now where he's long small RNAi peer Silence, he opts to selectively ignore publicly available data and smear $ARWR short. He WAS once a respected voice here."
and then a little piling on: "Always remember, Track Record counts, here you have few Twitter folks, one is a Biotech CEO and another a RNAi Phd Consultant both sold under $5. BOTH got it wrong.
Buy More and Thank Me Later !!"
and truthtracer puts a bow on the banter: "Most cogent thinkers agree $ARWR is well on their way to attaining a 10B-15B market cap within the next 1-2 yrs.
~Take the word of respected Analysts over drivel driven malcontents. It’s the smarter play."
the recent drop, like others, will subside and the march back up toward 100 will continue...when? anybody's guess...trust science, block out noise, buy more if you have the resources...and get an extra slice of pumpkin pie before it's all gone....one more thing...a nice Santa Barbara Pinot or Willamette Pinot, if you prefer Oregon varietals, pairs best with turkey. sip the cab after dessert.
Arrowhead Pharmaceuticals, Inc.
Goldman Sachs Equity Research, “We see this collaboration as logical given management’s focus on its cardiometabolic and pulmonary assets.” $ARWR $TKPHF from Truthtracer... so GS and SVB Leerink have both commented but no mention of new targets.. why is that?
from coldlander: $arwr $Amgen Amgen has filed phase two of AMG-890 on
. Estimated start date is June 10th. We should get a nice milestone payment on first dosing.
Frühjahrskeynote von Apple: Das iPhone kommt mit neuer Farbe
spot on news
Versicherungen gegen Impfschäden – sind die sinnvoll?
So funktioniert der digitale Impfpass
Yahoo Nachrichten Deutschland
© 2021 Verizon Media. Alle Rechte vorbehalten.
Haftungsausschluss für Daten
Über unsere Anzeigen